Ascletis Pharma (HKG:1672) said ASC47 the results for its new weight-loss drug, in combination with semaglutide, according to a Wednesday filing with the Hong Kong bourse.
In preclinical trials, the combination led to a 36.2% reduction in body weight in obese mice, outperforming semaglutide alone with muscle mass preserved.
The company plans further studies, with Phase II A results expected in 2025, aiming to advance obesity treatment options.
The pharmaceuticals shares were down by over 13% at day end.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。